EFFECT OF REPAGLINIDE COMBINED WITH METFORMIN IN THE TREATMENT OF ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS

Fengmin Liu¹, Wei Li², Jiangnan Zhang^{1, *}, E Chen^{3 ,*} 

¹Department of Endocrinology, Affiliated Fuzhou First Hospital of Fujian Medical University, Fuzhou, Fujian Province, China -  ²Department of Endocrinology, Wuhan No.1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China - ³Department of Neurosurgery, Zhongshan Hospital Affiliated to Xiamen University, Xiamen 361004, Fujian, China

Objective: To observe the efficacy and safety of repaglinide combined with metformin in the treatment of elderly patients with type 2 diabetes mellitus (T2DM).

Methods: 80 elderly patients with T2DM were randomly divided into the experience group and the control group, 40 cases in each group. Both groups were given regular diabetes diet, health education and proper exercise. The control group was treated with metformin, and the experience group was additionally treated with repaglinide on the basis of the control group. The clinical therapeutic effects and drug safety of the two groups were compared. The blood glucose levels of the two groups before and after treatment were observed, including fasting blood glucose (FBG), postprandial 2h blood glucose (2hPG), glycosylated hemoglobin (HbA1c), body mass index (BMI), oxidative stress indexes including malondialdehyde (MDA) and superoxide dismutase (SOD), recombinant secreted frizzled related protein 5 (SFRP5) , adiponectin (APN) and tumor necrosis factor α (TNF-a) and the occurrence of adverse reactions.

Results: The total effective rate of the experience group was 95%, which was significantly higher than 77.5% of the control group (P<0.05). There was no significant difference in the indicators between the two groups before treatment (P>0.05). After treatment, FBG, 2hPG, HbAlc and BMI in the experience group were significantly lower than those in the control group (P<0.05). In terms of oxidative stress indexes, after treatment, the level of NO and MDA in the experience group was significantly lower than that in the control group, and the level of SOD was significantly higher than that in the control group (P<0.05); After treatment, the level of SFRP5 and APN in the experience group was higher than that in the control group. The level of TNF- α was lower than that in the control group (P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion: Repaglinide combined with metformin is effective in the treatment of elderly patients with T2DM. It is effective in improving blood glucose levels, relieving oxidative stress and reducing the incidence of adverse reactions. It is safe and reliable for drug use. It is recommended to be widely promoted in clinical practice.